Metraipolis › archive › dc_0760cf8fe047

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with… — Europe PMC PMID:42292352

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42292352
DOI
10.3389/fimmu.2026.1771848
License (as archived)
solo-consultazione
Archived
2026-11-01T04:46:20.802Z
SHA-256 of the archived text
d8b1b36651373440e505fdf5b399fc25d08964c9da525704b93968c7a656b026
Stable URL of this page
https://metraipolis.com/documento/dc_0760cf8fe047

How to cite

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with… — Europe PMC PMID:42292352 — Europe PMC (en), https://europepmc.org/article/MED/42292352 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0760cf8fe047 (Metraipolis archive dc_0760cf8fe047, sha256 d8b1b36651373440e505fdf5b399fc25d08964c9da525704b93968c7a656b026)
BibTeX
@misc{dc0760cf8fe047,
  title = {Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with… — Europe PMC PMID:42292352},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42292352},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0760cf8fe047; sha256 d8b1b36651373440e505fdf5b399fc25d08964c9da525704b93968c7a656b026},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42292352. Agents can read the archived copy with the MCP tool read_document.